此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

用于围绝经期和绝经后女性性兴趣及唤起障碍的经皮睾酮凝胶 (TESTA MIND)

2026年9月27日 更新者:Aya Mohr Sasson、The University of Texas Health Science Center, Houston

用于围绝经期和绝经后女性性兴趣和唤起障碍的经皮睾酮凝胶 - 一项改善性兴趣和欲望的随机、双盲、安慰剂对照试验

Hypoactive sexual desire disorder (HSDD) is described as the most common form of female sexual dysfunction, particularly affecting peri- and postmenopausal women and is associated with significant distress and reduced quality of life. The TESTA-MIND study will evaluate the efficacy and safety of a standardized compounded transdermal testosterone gel in a randomized, double-blind, placebo-controlled design to address the lack of FDA-approved options and limited high-quality evidence for treating decreased libido in women.

研究概览

详细说明

Hypoactive sexual desire disorder (HSDD) is the most prevalent form of female sexual dysfunction, particularly affecting peri- and postmenopausal women. Epidemiological studies estimate that between 8-14% of postmenopausal women experience clinically significant reductions in sexual desire that cause distress or interpersonal difficulty, significantly impacting quality of life and intimate relationships. In 2013, with the publication of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), the diagnosis of HSDD was merged with female sexual arousal disorder under the category of Female Sexual Interest/Arousal Disorder (FSIAD). Despite this reclassification, clinical and pharmacological trials continue to use HSDD criteria, given their clearer operationalization and applicability in interventional studies.

Testosterone has long been recognized as a key modulator of female sexual desire and arousal. Observational studies show that circulating androgen levels decrease substantially with age and after menopause. Clinical trials of transdermal testosterone have demonstrated improvements in sexual function, specifically increased frequency of satisfying sexual events, enhanced desire, and reduced distress compared with placebo (7-9). Nevertheless, most clinical studies have utilized pharmaceutical-grade formulations not currently available in the United States, leading many clinicians to rely on compounded testosterone creams.

Currently, no FDA-approved testosterone therapy exists for women, and off-label use varies widely in formulation and administration. Transdermal preparations may provide a physiologic, steady release, and offer practical advantages over patches or systemic therapy, but robust randomized data remain scarce.

Evidence regarding compounded testosterone is limited and highlights concerns about variability in formulation, dosing accuracy, and absorption. Professional societies caution against the routine use of compounded hormones, citing the lack of FDA oversight, inconsistent bioavailability, and absence of long-term safety data. While compounded testosterone may represent a pragmatic solution in the absence of FDA-approved formulations, its use requires rigorous evaluation under standardized trial conditions to establish both efficacy and safety.

The TESTA-MIND study is designed to address this evidence gap by investigating the efficacy and safety of a standardized compounded testosterone gel in peri- and postmenopausal women with decreased libido. By conducting a randomized, double-blind, placebo-controlled trial, the investigators aim to provide high-quality data on the therapeutic role of testosterone in this underserved population, while addressing the clinical uncertainty and professional society concerns that currently limit its widespread adoption.

研究类型

介入性

注册 (估计的)

150

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Texas
      • Houston、Texas、美国、77030
        • University of Texas

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

40年 至 65年 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

女性

描述

Inclusion Criteria

  • Women 40-65 years; peri- or postmenopausal - with one of the following:

    • Staging by STRAW+10: stage (-2) or above
    • amenorrhea ≥12 mo
    • Follicle stimulating hormone in menopausal range
  • FSIAD diagnosis according to the DSM-5: (3/5 of the following symptoms)

    • reduced or no interest in sex
    • few or no thoughts about sex
    • decreased sexual arousal or pleasure during sexual activity
    • reduced or no arousal in response to visual, written, or verbal cues
    • infrequent or no initiation of sexual activity within a relationship
    • reduced or no sensations in the genitals

They must also have:

  • symptoms lasting 6 months or more

  • significant distress about their symptoms

  • symptoms that are not more accurately explained by a nonsexual mental health disorder, domestic abuse, medication, substance abuse, or another medical condition

    • In a stable relationship or sexually active opportunity (as defined by participant)
    • If on systemic estrogen ± progestin or local vaginal estrogen: stable dose ≥8 weeks before randomization and agrees to remain stable
    • Able to consent and comply with study procedures

Exclusion Criteria

  • Current or recent (≤8 weeks) androgen therapy, dehydroepiandrosterone (DHEA), or anabolic steroids
  • Total T above premenopausal upper physiologic range at baseline (>55 ng/dL)
  • History of hormone-dependent malignancy, untreated endometrial hyperplasia, or active gynecologic malignancy
  • Active severe psychiatric disorder (e.g., untreated major depression), substance use disorder, or relationship violence that precludes attribution of effect
  • Uncontrolled thyroid disease, significant liver disease, increased liver enzymes, or high cardiovascular risk judged unsafe by the primary care provider
  • Pregnancy, attempting conception, or breastfeeding
  • Dermatologic conditions preventing transdermal use; known hypersensitivity to the gel components

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
有源比较器:Transdermal testosterone treatment

Transdermal gel testosterone treatment that will be provided by a clicker

The compounded testosterone gel will be administered using a metered-dose delivery system calibrated to dispense 0.25 mL per actuation, corresponding to an estimated systemic exposure of approximately 300 µg of testosterone per day, within the physiologic range for females.

安慰剂比较:Placebo

Transdermal gel placebo treatment that will be provided by a clicker

A testosterone-free compounded gel will be delivered via a metered-dose pump calibrated to dispense 0.25 mL per actuation. The placebo gel will use an identical metered-dose delivery system, packaging, and administration instructions.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
The Female Sexual Function Index score
大体时间:On recruitment, and at 4,8, and 12 weeks of treatment

The Female Sexual Function Index (FSFI) is a widely used, 19-item self-report questionnaire assessing women's sexual health across six domains: desire, arousal, lubrication, orgasm, satisfaction, and pain. Responses are rated on scales (1-5), with higher scores indicating better function, and these are combined to form domain and total scores.

On recruitment, and at 4,8, and 12 weeks of treatment

次要结果测量

结果测量
措施说明
大体时间
Patient global impression of improvement
大体时间:On recruitment, and at 4,8, and 12 weeks of treatment

This score uses a 7-point rating scale, ranging from 7=Very Much Improved to 1= Very Much Worse.

On recruitment, and at 4,8, and 12 weeks of treatment
Side effects of the treatment
大体时间:On recruitment, and at 4,8, and 12 weeks of treatment

Including any of the following: acne, hirsutism, alopecia, voice change, clitoromegaly, and application-site reactions.

On recruitment, and at 4,8, and 12 weeks of treatment

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2027年1月1日

初级完成 (估计的)

2028年3月30日

研究完成 (估计的)

2028年3月30日

研究注册日期

首次提交

2026年2月6日

首先提交符合 QC 标准的

2026年2月6日

首次发布 (实际的)

2026年2月13日

研究记录更新

最后更新发布 (实际的)

2026年9月29日

上次提交的符合 QC 标准的更新

2026年9月27日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

其他研究编号

  • HSC-MS-26

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅